Even though there hasn't been much public discussion from the Obama administration in regards to contingency plans should the Supreme Court rule in favor of the plaintiffs in King v. Burwell, there is likely much talk going on behind the scenes, explained Susan Dentzer, senior health policy adviser at the Robert Wood Johnson Foundation.
Even though there hasn’t been much public discussion from the Obama administration in regards to contingency plans should the Supreme Court rule in favor of the plaintiffs in King v. Burwell, there is likely much talk going on behind the scenes, explained Susan Dentzer, senior health policy adviser at the Robert Wood Johnson Foundation.
The administration actually has little to gain from talking about creating contingency plans since it is of the belief that the law deserves to upheld, as Solicitor General Donald Verrilli explained.
While she is of the belief that based on oral arguments there are 5 votes Court to uphold the law, the justices will have their own reasons for voting that way.
“There won’t be a single opinion to say the least,” Ms Dentzer says. “There very rarely is with the Supreme Court. But I think the administration is doing its best to think about how it could blunt the effects of it.”
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities
July 30th 2025Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.
Read More